Halopex 10 mg 30 Tablets Sixpex USA

Product Overview

Halopex 10 mg 30 Tablets Sixpex USA contains fluoxymesterone (9α-fluoro-11β-hydroxy-17α-methyltestosterone), the highly potent C9-fluorinated anabolic steroid identical to Schedule III Halotestin 10 mg tablets. Each sealed unit delivers precisely 30 tablets—the exact count found in regulated CIII bottling—for seamless institutional catalog integration and DEA-compliant inventory control.

Sixpex USA’s domestic production replicates USP monograph specifications (white, scored tablets; C21H29FO3) while maintaining U.S. warehousing eliminating customs exposure. This authentic 10 mg/30-tab presentation serves specialist platforms where advanced buyers demand pharmaceutical-grade verification matching legitimate Halotestin workflows rather than underground approximations.

Halopex targets CIII-authorized performance researchers exclusively, prioritizing controlled substance compliance over general supplement positioning without protocols or outcome claims.

Brand & Manufacturer Information

Sixpex USA manufactures DEA Schedule III anabolics including Halopex through performance-grade domestic facilities serving institutional resellers requiring Form 222 traceability. The exact 10 mg/30-tab Halotestin match maintains catalog continuity alongside Sixpex Oxapex while USP-equivalent morphology distinguishes legitimate CIII product from powder conversions.

Domestic positioning supports encrypted DEA-compliant platforms confirming fluoxymesterone identity/potency distinguishing from non-pharmaceutical alternatives prevalent across Schedule III channels.

Active Compound Information

Halopex contains fluoxymesterone, C9α-fluorinated 17α-methyltestosterone exhibiting extreme androgenic potency (~1900:850 rating) with no aromatization and short 9.2-hour half-life necessitating frequent dosing. Molecular weight 336.45; Schedule III classification reflects hepatotoxicity, cardiovascular risk profile, and virilization intensity distinguishing from milder orals.

10 mg strength matches FDA-approved Halotestin while 30-tablet count replicates CIII pharmacy dispensing units. WADA S1a prohibited; regulated 21 CFR 1308.13. Listing identifies pharmaceutical specifications exclusively.

Product Specifications

• Product name: Halopex 10 mg 30 Tablets Sixpex USA

• Brand/manufacturer: Sixpex USA

• Active compound: Fluoxymesterone (C21H29FO3)

• Strength: 10 mg per scored tablet

• Quantity per pack: 30 tablets

• Dosage form: Oral scored tablets

• Category: Schedule III anabolic steroid

• Appearance: White, round, scored (Halotestin USP match)

• Primary packaging: CIII-compliant HDPE bottle

• Label elements: 10 mg, total count, DEA warnings, batch code

Quality Control & Testing Standards

Fluoxymesterone 10 mg requires USP identity (IR spectroscopy), potency assay (98-102% HPLC), and dissolution (Q=85% 45 min) per Schedule III monograph. Sixpex maintains batch documentation verifying C21H29FO3 identity, uniform content, and CIII-compliant stability excluding contraindicated excipients.

30-tablet authentic bottling prevents diversion matching legitimate Halotestin pharmacy supply; domestic warehousing maintains 36-month stability per accelerated protocols.

Intended Use & Market Positioning

Halopex 10 mg serves CIII-authorized institutional performance researchers exclusively. Exact Halotestin match excludes crossover positioning within verified DEA-compliant catalogs serving licensed 21+ clientele. Zero protocols represented.

Packaging, Storage & Handling

CIII-compliant sealed bottles protect light-sensitive fluoxymesterone; controlled 20-25°C locked per DEA. Facilities maintain Form 222 lot logs supporting regulatory audits.

Purchasing & Availability Information

Domestic CIII platforms provide encrypted Form 222 checkout, institutional verification, discreet Priority fulfillment from Sixpex U.S. facilities. 10 mg/30-tab SKU authenticates legitimate Halotestin-equivalent institutional product.

Legal & Regulatory Disclaimer

Fluoxymesterone constitutes DEA Schedule III controlled substance; non-medical distribution/possession violates 21 USC §812. Buyer assumes complete DEA licensing/Form 222 compliance; zero medical claims/protocols provided.